Director-led regulatory strategy, clinical development and Australian market-entry support for pharmaceutical, biotechnology, medical technology and other life-sciences organisations — from early development and clinical trials through to TGA registration and lifecycle management.
Tricode Clinical provides specialist Australian regulatory, clinical development and Local Sponsor support to pharmaceutical, biotechnology, medical technology and other life-sciences organisations. We combine senior regulatory advice with practical execution, helping clients navigate Australian requirements and progress programmes with greater clarity and confidence.
Tricode Clinical is a specialist Australian regulatory consultancy supporting pharmaceutical, biotechnology, medical technology and other life-sciences organisations across clinical development, regulatory strategy, marketing authorisation and product lifecycle activities.
We provide senior, Director-led Australian regulatory support for local and international programmes.
Tricode Clinical is led by Peter Lynch, Founder and Director, who brings more than 25 years of regulatory affairs experience. His background includes working within the Therapeutic Goods Administration and serving as Country Head of Regulatory Affairs for Australia and New Zealand at a major global CRO, supporting multi-jurisdictional programmes across APAC, Europe and North America.
Peter has acted as a key interface with the TGA, Medsafe and the Office of the Gene Technology Regulator across clinical trial and marketing authorisation programmes. His experience spans CTN and CTA pathways, marketing authorisation strategy, advanced therapies, gene technology and product lifecycle management.
Clients work directly with the Director throughout the engagement. There are no layered account teams or unnecessary organisational handovers.
Director-led Australian regulatory support for CTN and CTA pathway planning, HREC coordination and study start-up, working alongside sponsor, CRO and site teams.
Clients engage Tricode when they need senior Australian regulatory judgement, ownership of a defined workstream or an appropriate Australian regulatory presence.
For organisations adding Australia to a global development or commercialisation programme and needing clarity on local pathways, sequencing and responsibilities.
For programmes where pathway selection, Australian interpretation or TGA-facing decisions require experienced local expertise.
For sponsors that need a senior Australian regulatory partner to lead a specific activity or interface, including trial start-up, alongside existing programme structures.
For organisations needing Local Sponsor or Regulatory Agent support with clearly defined responsibilities and accountability.
Ways to engage
Senior strategic adviceRegulatory judgement, pathway strategy, review and advisory support.
Defined regulatory executionOwnership and delivery of agreed Australian regulatory workstreams.
Australian regulatory presenceLocal Sponsor or Regulatory Agent responsibilities where appropriate.
Clients work directly with the Director across both regulatory strategy and delivery.
Advice grounded in Australian regulatory requirements and their practical application to global development programmes.
Regulatory decisions considered alongside clinical development, international sequencing, market-entry and lifecycle objectives.
Tricode can provide senior regulatory advice, lead defined Australian workstreams or integrate with internal teams, CROs and other providers where specialist Australian expertise is required.
Australia can play a valuable role in global development and commercialisation programmes, supported by a high-quality clinical research environment and an established regulatory framework.
Experienced investigators, high-quality research infrastructure and internationally recognised capabilities support early and later-stage clinical development.
TGA pathways and established ethics and governance processes provide a defined environment for Australian clinical and regulatory activities.
Australian activities can form part of broader international development, registration and commercialisation planning across global and regional programmes.
Regulatory and market-access insights for organisations evaluating Australian pathways, clinical development opportunities and the interaction between registration, reimbursement and commercial planning.
Download the ReportA practical checklist covering CTN vs CTA pathways, required documents, HREC requirements, and common pitfalls to avoid.
Key requirements for clinical trials involving GMOs, including DNIR vs DIR pathways, IBC processes, and common pitfalls.
Clear comparison of the different models available to meet Australia’s Local Sponsor requirements, including pros and considerations.
Tell us about your programme, regulatory priorities or planned Australian activities. Tricode Clinical will review your enquiry and contact you to arrange an initial discussion.
Prefer email? You can also contact Tricode Clinical at info@tricodeclinical.com.au.